Global Fabry Disease Market, By Type (Type 1, Type 2, Others), Diagnosis (Blood Test, Genetic Test, Parenteral Test, Others), Treatment (Enzyme Replacement Therapy, Oral Therapy, Adjunct Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Fabry Disease Market Analysis and Size
The fabry disease market is expected to witness significant growth during the forecast period. Rising prevalence of autoimmune inherited disorders worldwide and emerging markets are the factors responsible for the growth of this market. Numerous R&D activities and potential approval of promising pipeline products, including substrate reduction therapies and enzyme replacement therapies, are estimated to increase the growth rate in the forecast period. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the fabry disease market in the forecast period 2022-2029. The expected CAGR of l fabry disease market is tend to be around 7.30% in the mentioned forecast period. The market was valued at USD 1053.21 million in 2021, and it would grow upto USD 1850.60 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Fabry disease is a rare inherited disorder of glycosphingolipid metabolism, resulting absent activity of lysosomal enzyme (α-galactosidase A) due to this it is belong to the lysosomal storage disorders. It is an X-linked inherited disorder, mainly affects the male population and can be life-threating. This enzymatic deficiency is caused by alteration in α-galactosidase A, due to this breakdown of sugar lipid dose not occurs. Symptoms of fabry diseases include episodes of pain, angiokeratomas, reduced sweating ability, corneal opacity, hearing loss, kidney damage, heart attacks, strokes, and anaemia among others.
Fabry Disease Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Type 1, Type 2, Others), Diagnosis (Blood Test, Genetic Test, Parenteral Test, Others), Treatment (Enzyme Replacement Therapy, Oral Therapy, Adjunct Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), Merck KGaA (Germany), Sanofi (France), Biocare Medical, LLC (U.S.), Eli Lilly and Company (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Mitsubishi Chemical Group Corporation (Japan), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), Teva Pharmaceuticals Industries Ltd. (Israel), AstraZeneca (U.K.), JCR Pharmaceuticals Co., Ltd (Japan), Idorsia Pharmaceuticals Ltd (Switzerland), Plant-Based Proteins With Better Therapeutics Profiles (Israel)
|
|
Market Opportunities
|
|
Global Fabry Disease Market Dynamics
Drivers
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
- Increase Demand of Enzyme Replacement Therapy
Enzyme replacement therapy is expected to boost the market growth as this therapy is known to be the only specific treatment for Fabry disease. This therapy is expected to improve the quality of life of patients. The increasing awareness associated with Fabry disease within the healthcare community is expected to support the growth of enzyme replacement therapy segment. This boost the market growth
Opportunities
- Increase in Technological Advancements
Technological advancements and discovery of novel therapies are expected to boost the market growth. For instance, Sanofi’s Fabrazyme and Shire’s Replagal, have been approved in Europe, and Fabrazyme has been approved in the U.S. Current clinical trials are performed focusing on the safety and efficacy profile of enzyme replacement therapies and introduction of novel oral therapies which can eliminate the need for intravenous infusions. This boosts the market growth.
- Increasing Demand for Retail Pharmacies
The rise in the number of narcotic drugs delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Development of Complications
There are several complications that gets associated with the disease and these could curb the growth of the global fabry disease market over a forecast period. Fabry disease is associated with complications such as progressive kidney failure, heart failure, and stroke. All these factors restrict the growth of the market.
- High Cost
The huge expenditure associated with these agents surely hamper the market growth.
This fabry disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the fabry disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Fabry Disease Market
The COVID-19 pandemic is expected to increase the demand for the treatment for Fabry disease as patients with this rare disorder are vulnerable to serious complications. Many of the patients experienced a block in their treatment during to the pandemic due to the fear of infection. In the post-pandemic era, with lesser number of cases of COVID-19, Fabry disease patients are managed to obtain regular treatment which will boost the industry growth over the foreseeable future.
Global Fabry Disease Market Scope
The global fabry disease market is segmented on the basis of type, diagnosis, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Type 1
- Type 2
- Others
Diagnosis
- Blood Test
- Genetic Test
- Parenteral Test
- Others
Treatment
- Enzyme Replacement Therapy
- Oral Therapy
- Adjunct Therapy
- Others
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Global Fabry Disease Market Regional Analysis/Insights
The global fabry disease market is analysed and market size insights and trends are provided by type, diagnosis, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global fabry disease market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for global fabry disease market due to advancement in technology for diagnosis of rare disease using ICD and increasing initiatives taken by the pharmaceutical organizations to generate novel formulation.
Asia-Pacific dominates the market due to increasing initiatives taken by the government and pharmaceutical organizations to spread awareness and presence of generic manufacturer.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Fabry Disease Market Share Analysis
The global fabry disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global fabry disease market
Key players operating in the global fabry disease market include:
- Pfizer Inc. (U.S.)
- Merck KGaA (Germany)
- Sanofi (France)
- Biocare Medical, LLC (U.S.)
- Eli Lilly and Company (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Mitsubishi Chemical Group Corporation (Japan)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc. (U.K.)
- Bayer AG (Germany)
- Teva Pharmaceuticals Industries Ltd. (Israel)
- AstraZeneca (U.K.)
- JCR Pharmaceuticals Co., Ltd (Japan)
- Idorsia Pharmaceuticals Ltd (Switzerland)
- Plant-Based Proteins With Better Therapeutics Profiles (Israel)
SKU-